U.S. Firm's Earnings To Remain Robust Through 2023
Source: Andrew Semple   (5/25/23)
Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report. More >

Animal Feed Company Evaluating Strategic Alternatives
Source: Streetwise Reports  (5/23/23)
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit. More >

Wellness Co.'s Q1/23 Results Better Than Expected
Source: Andrew Semple  (5/19/23)
Results for the first quarter of this year for Ayr Wellness Inc. were better than expected, reported an Echelon Capital Markets research note. More >

Telehealth Co. Signs Contract With US Health Plan Serving 1 Million Patients
Source: Streetwise Reports  (5/18/23)
Telehealth company Reliq Health Technologies signs a contract with a U.S. health plan that operates in five states with over 3,000 doctors and more than 1 million patients. More >

Biopharma Co. Ceases Program to Optimize Resources
Source: Hartaj Singh  (5/16/23)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report. More >

Digital Health Co. Grows Revenue and Reduces Expenses
Source: Rob Goff   (5/10/23)
This Canadian healthcare tech company is showing projected returns of over 241% for investors, noted an Echelon Capital Markets research note. More >

Telehealth Co. Expands into Arkansas
Source: Streetwise Reports  (5/5/23)
Telehealth company Reliq Health Technologies signs five new contracts in four states for its iUGO platform, including its first contract in the state of Arkansas, where chronic diseases cost billions annually. More >

Pharmaceutical Company Sets Gold Standard for New Drugs
Source: Streetwise Reports  (4/26/23)
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history. More >

Adding Silver a Solid Move
Source: Michael Ballanger  (4/24/23)
Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market. More >

As Countries Bolster Defense, Opportunities Emerge
Source: Streetwise Reports  (4/21/23)
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability. More >

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial
Source: Streetwise Reports  (4/19/23)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill. More >

Co.'s New Cell Therapy Shows Positive Effects
Source: Emily Bodnar  (4/19/23)
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report. More >

Blockchain Co., Vets Group Team Up for App
Source: Streetwise Reports  (4/19/23)
A Vancouver blockchain company is partnering with a leading veterans advocacy group to launch a medical cannabis education and reward application for vets. More >

Oncology Co. Receives Buy Rating for New Drug Trials
Source: Dr. Joseph Pantginis  (4/18/23)
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report. More >

Biotech Rated Outperform Advances Top Drug Candidate
Source: Dr. David Nierengarten  (4/18/23)
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report. More >

Trial Results of New Pneumococcal Vaccine Compelling
Source: Dr. Thomas Shrader   (4/18/23)
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report. More >

Follow-up Results From T2 Diabetes Trial Positive
Source: Dr. Jonathan Aschoff   (4/14/23)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report. More >

CEO: Telehealth Co. in 'More Comfortable Cash Position'
Source: Streetwise Reports  (4/14/23)
Telehealth company Reliq Health Technologies Inc. expects to be profitable for the quarter ending in June and initiate a share buyback program this year, its CEO told shareholders this week. More >

Biotech Co. Set To Reach New Highs
Source: Streetwise Reports  (4/13/23)
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics. More >

Phase 3 Trial in Progress of New Ichthyosis Treatment
Source: Dr. Ram Selvaraju  (4/12/23)
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Appoints Industry Experts in Key Positions
Source: Streetwise Reports  (4/11/23)
Recently, Appili Therapeutics Inc. (APLI.TSX) appointed a new director of non-clinical research and director of new product development. Read to see who these people are, what upcoming catalysts there are for the company, and what experts are saying. More >

Phase 2b Trial of New Drug for Ovarian Cancer Starts
Source: Dr. Joseph Pantginis   (4/11/23)
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report. More >

Safety Data From One Trial of New Drug Helpful to Another
Source: Ed Arce  (4/5/23)
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Will 'Not Look Back' From Here
Source: Clive Maund  (4/5/23)
In light of its recent development of a product that purportedly has the ability to reset damaged DNA, technical analyst Clive Maund takes a look at Resverlogix Corp. More >

Firm Grows Revenue 38% in Q4/22
Source: Andrew Semple  (4/4/23)
The company's material increase in profitability during the quarter is a healthy step toward reaching free cash flow break even status, noted an Echelon Capital Markets report. More >